Neuropathology, Genetics and Biomarker Core

$177,083P30FY2011AGNIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 39713873 Paper 39711228 Paper 39677464 Paper 39379761 Paper 39254167 Paper 39228745 Paper 39207439 Paper 39173101 Paper 39003411 Paper 38980643 Paper 38958543 Paper 38958117 Paper 38949538 Paper 38915636 Paper 38883718 Paper 38721926 Paper 38712163 Paper 38662500 Paper 38641585 Paper 38610104 Paper 38460116 Paper 38441951 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38356471 Paper 38275389 Paper 38244935 Paper 38198547 Paper 38194584 Paper 38133963 Paper 37801072 Paper 37797545 Paper 37592813 Paper 37580727 Paper 37528055 Paper 37491248 Paper 37322115 Paper 37300313 Paper 37260021 Paper 37256497 Paper 37245492 Paper 37243937 Paper 37212114 Paper 37057867 Paper 37051669 Paper 37041649 Paper 37038809 Paper 36997127 Paper 36970907 Paper 36946449 Paper 36840665 Paper 36758620 Paper 36722399 Paper 36710669 Paper 36681388 Paper 36648159 Paper 36628434 Paper 36621368 Paper 36617779 Paper 36577280 Paper 36572909 Paper 36565204 Paper 36537275 Paper 36530083 Paper 36518085 Paper 36482861 Paper 36476106 Paper 36394443 Paper 36379194 Paper 36324086 Paper 36314203 Paper 36308307 Paper 36289630 Paper 36264254 Paper 36253382 Paper 36251929 Paper 36239248 Paper 36220593 Paper 36189595 Paper 36178120 Paper 36097795 Paper 36093697 Paper 36072364 Paper 36068552 Paper 36062452 Paper 36031904 Paper 36031892 Paper 35894783 Paper 35871325 Paper 35842477 Paper 35797594 Paper 35768831 Paper 35737506 Paper 35699222 Paper 35640459 Paper 35551470 Paper 35531707 Paper 35513767 Paper 35444054

Abstract

PROJECT SUMMARY: Neurodegenerative disorders are characterized by abundant protein aggregates in brain and spinal cord (CNS) that are the defining neuropathology (NP) of these disorders as exemplified by senile plaques (SPs) and neurofibrillary tangles (NFTs), the diagnostic signatures of Alzheimer's disease (AD). However, AD is associated with Lewy bodies (LBs) and TDP-43 pathologies in >50% of patients while mild cognitive impairment (MCI) often shows abundant SPs and NFTs at autopsy consistent with AD. Further, the NP in ~25% or more of frontotemporal lobar degeneration (FTLD) patients is AD, while the remaining FTLD cases are non-AD tauopathies (FTLD-Tau), TDP-43 proteinopathy (FTLD-TDP) or, rarely, FUS proteinopathy (FTLD-FUS). Thus, a definitive diagnosis of AD and related dementias is established definitively only by postmortem NP examination, and an accurate NP diagnosis is essential for informative clinicopathologic correlations to elucidate molecular mechanisms of MCI, AD, FTLD and other dementias such as Parkinson's disease with dementia and dementia with LBs. Since multiple genetic factors contribute to the risk for AD and biomarkers signal disease onset/progression, DNA and biofluid banking is critical for genetic and biomarker studies. Hence, the University of Pennsylvania (Penn) AD Core Center (ADCC) characterizes and banks CNS tissues, DNA and biofluids from well-characterized patients followed in Clinical Core B with AD and related disorders as well as normal control subjects. This is essential for research conducted in ADCC Pilots and other grants that utilize Penn ADCC resources. Accordingly, Core D is re-named the Neuropathology, Genetics and Biomarker Core to reflect the full scope of its current activities. Core D also distributes tissue, DNA and biofluids to investigators at and beyond Penn for research. Finally, Core D works with the Data Management and Statistics Core C to enter all information into a database, maintain data confidentiality, and provide these data to NACC. In summary, Core D performs critical functions to support the mission of the Penn ADCC.

View original record on NIH RePORTER →